| dbo:abstract
|
- Le taranabant (nom de code MK-0364) est un agoniste inverse des récepteurs cannabinoïdes CB1 qui a été testé comme traitement potentiel de l'obésité du fait de ses propriétés anorexigènes. Il est issu des laboratoires Merck & Co. En octobre 2008, Merck a arrêté les essais cliniques de phase III à la suite d'effets secondaires importants notamment des dépressions et des syndromes anxieux. (fr)
- Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. It was discovered by Merck & Co. In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central nervous system side effects, mainly depression and anxiety. (en)
|
| dbo:casNumber
| |
| dbo:fdaUniiCode
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 5375 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:alt
|
- Skeletal formula of taranabant (en)
- Space-filling model of the taranabant molecule (en)
|
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:cl
| |
| dbp:f
| |
| dbp:h
| |
| dbp:image
|
- Taranabant 3D spacefill.png (en)
|
| dbp:iupacName
|
- N-[-4--3--2-butanyl]-2-methyl-2-{[5--2-pyridinyl]oxy}propanamide (en)
|
| dbp:legalStatus
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
|
- C[C@@H]NCCOC3=NC=CCF (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- QLYKJCMUNUWAGO-GAJHUEQPSA-N (en)
|
| dbp:unii
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:width
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Le taranabant (nom de code MK-0364) est un agoniste inverse des récepteurs cannabinoïdes CB1 qui a été testé comme traitement potentiel de l'obésité du fait de ses propriétés anorexigènes. Il est issu des laboratoires Merck & Co. En octobre 2008, Merck a arrêté les essais cliniques de phase III à la suite d'effets secondaires importants notamment des dépressions et des syndromes anxieux. (fr)
- Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. It was discovered by Merck & Co. In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central nervous system side effects, mainly depression and anxiety. (en)
|
| rdfs:label
|
- Taranabant (fr)
- Taranabant (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
